SEMABIZ, Inc. | ChosaReport.com

日本と海外の市場調査レポート＆サービスを取り扱っております。

カスタム抗体市場 : 2029年までの世界予測

Custom Antibody Market - Global Forecast to 2029

カスタム抗体市場 : サービス (開発、精製、断片化、標識)、タイプ (mAbs、pAbs、rAbs)、ソース (ウサギ、マウス)、用途 (研究、治療)、適応症 (腫瘍学、免疫学、感染症、CVD) - 2029年までの世界予測
Custom Antibody Market by Service (Development, Purification, Fragmentation, Labeling), Type (mAbs, pAbs, rAbs), Source (Rabbit, Mice), Application (Research, Therapeutics), Indication (Oncology, Immunology, Infectious, CVD) - Global Forecast to 2029
出版年月2024年6月
ページ数377
図表数524
価格タイプシングルユーザライセンス
価格USD 4,950
種別英文調査報告書

The custom antibody market is expected to reach USD 901 million in 2029 from USD 579 million in 2024, at a CAGR of 9.2% during the forecast period.

カスタム抗体市場は、予測期間中のCAGR 9.2%で、2024年の5億7,900万米ドルから2029年には9億100万米ドルに達すると予想されています。

カスタム抗体市場 : 2029年までの世界予測

The growth of this market can be attributed to the increasing prevalence of chronic diseases such as cancer, autoimmune disorders, and infectious diseases, which has heightened the demand for targeted and effective therapeutic antibodies. Advancements in biotechnology and genetic engineering have significantly improved the development and production of custom antibodies, enhancing their specificity and efficacy.

カスタム抗体市場 : 2029年までの世界予測 ecosystem

“The antibody development segment accounted for the largest share by service in the custom antibody market 2023.”
The custom antibody market by service is segmented into antibody development, antibody production & purification, and antibody fragmentation & labeling. The antibody development is further subsegmented into antigen preparation, immunization & hybridoma production, and antibody characterization. In 2023, the antibody development segment accounted for the largest share of the service segment in the global custom antibody market. Factors such as the increasing use of antibodies in drug delivery systems, such as antibody-drug conjugates (ADCs), has expanded the need for custom antibody development.

“The Asia Pacific region is growing at the highest CAGR in the custom antibody market from 2024 to 2029.”
The Asia Pacific region is expected to grow at the highest growth rate during the forecast period. Various factors including emerging economies, increased prevalence of chronic diseases, and large patient pool undergoing advanced medical treatment are factors driving the high growth of the APAC market.
Increased research investments from government funding are expected to boost the growth of the custom antibody market in the Asia Pacific region. As the region continues to invest in drug development, there is a growing demand for research antibodies driving demand for custom antibodies.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: C-level Executives – 55%, Director-level – 20%, and Others – 25%
• By Region: North America -45%, Europe -20%, Asia-Pacific -20%, Latin America -10%, Middle East -3%, and Africa-2%.

カスタム抗体市場 : 2029年までの世界予測 region

List of Companies Profiled in the Report:
• Thermo Fisher Scientific Inc. (US)
• GenScript (US)
• Merck KGaA (Germany)
• Bio-Rad Laboratories, Inc. (US)
• Agilent Technologies, Inc. (US)
• Revvity, Inc. (US)
• Bio-Techne (US)
• ROCKLAND IMMUNOCHEMICALS, INC. (US)
• Laboratory Corporation of America Holdings (US)
• Inotiv (US)
• Danaher Corporation (US)
• Sino Biological, Inc. (China)
• KANEKA CORPORATION (Japan)
• OriGene Technologies, Inc. (US)
• Absolute Biotech (US)
• Biointron Biologics (China)
• Cell Signaling Technology, Inc. (US)
• Curia Global, Inc. (US)
• Mabtech (Sweden)
• ACROBiosystems (US)
• Elabscience Bionovation Inc. (US)
• Creative Diagnostics (US)
• CUSABIO TECHNOLOGY LLC (US)
• BioGenes GmbH (Germany)
• RayBiotech, Inc. (US)
• Proteintech Group, Inc (US)
• IMGENEX INDIA Pvt Ltd. (India)
• Synbio Technologies (US)
• ProSci Incorporated (US)
• Creative Biolabs (US)

Research Coverage:
This research report categorizes the custom antibody market by service (antibody development (antigen preparation, immunization & hybridoma production, and antibody characterization), antibody production & purification, and antibody fragmentation & labeling, type (monoclonal antibodies, polyclonal antibodies, recombinant antibodies, and others), source (mice, rabbits, and others), application (research, and therapeutics), indication (oncology, infectious diseases, immunology, neurobiology, cardiovascular diseases, and other indications), end user (pharmaceutical & biotechnologies companies, academic & research institutes, and contract research organizations), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The report provides in-depth information on significant factors influencing the growth of the custom antibody market, including drivers, trends, challenges, and opportunities. A thorough analysis of major industry players has been undertaken to provide insights into their business profiles, services, key strategies, collaborations, partnerships, and agreements. Additionally, the report encompasses recent developments such as new product launches, and acquisitions within the custom antibody market.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall custom antibody market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:
Analysis of key drivers (growing importance of custom antibodies in precision medicine, use of antibodies in biomarker identification and validation, rising research activities and funding investments for antibody development, advancement in biotechnology and genetic engineering), restraints (High cost and time-consuming antibody development from transgenic animals), opportunities (rising therapeutic and diagnostic application of antibodies, high scope for growth in emerging economies), and challenges (challenges associated with safety and stability) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly launched services of the custom antibody market
• Market Development: Comprehensive information about lucrative markets – the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the custom antibody market
• Competitive Assessment: Thermo Fisher Scientific Inc. (US), GenScript (US), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Agilent Technologies, Inc. (US), Revvity, Inc. (US), Bio-Techne (US), ROCKLAND IMMUNOCHEMICALS, INC. (US), Laboratory Corporation of America Holdings (US), Inotiv (US), Danaher Corporation (US), Sino Biological, Inc. (China), KANEKA CORPORATION (Japan), OriGene Technologies, Inc. (US), Absolute Biotech (US), Biointron Biologics (China), Cell Signaling Technology, Inc. (US), Curia Global, Inc. (US), Mabtech (Sweden), ACROBiosystems (US), Elabscience Bionovation Inc. (US), Creative Diagnostics (US), CUSABIO TECHNOLOGY LLC (US), BioGenes GmbH (Germany), RayBiotech, Inc. (US), Proteintech Group, Inc (US), IMGENEX INDIA Pvt Ltd. (India), Synbio Technologies (US), ProSci Incorporated (US), Creative Biolabs (US) among others in the market.

Table of Contents

1            INTRODUCTION            51

1.1         STUDY OBJECTIVES      51

1.2         MARKET DEFINITION   52

1.2.1      INCLUSIONS AND EXCLUSIONS OF STUDY         52

1.3         MARKET SCOPE             53

1.3.1      MARKETS COVERED     53

1.3.2      REGIONS COVERED      54

1.4         YEARS CONSIDERED     54

1.5         CURRENCY CONSIDERED          55

1.6         STAKEHOLDERS            55

1.7         SUMMARY OF CHANGES            55

1.8         RECESSION IMPACT      56

2            RESEARCH METHODOLOGY     57

2.1         RESEARCH DATA           57

FIGURE 1           RESEARCH DESIGN       57

2.1.1      SECONDARY DATA       58

2.1.2      PRIMARY DATA 59

FIGURE 2           CUSTOM ANTIBODY MARKET: BREAKDOWN OF PRIMARIES              59

2.2         MARKET ESTIMATION METHODOLOGY            60

FIGURE 3           CUSTOM ANTIBODY MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023    60

2.2.1      MARKET ESTIMATION  60

FIGURE 4           MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023             61

FIGURE 5           ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.:  REVENUE SHARE ANALYSIS (2023)           61

2.2.1.1   Insights of primary experts 63

FIGURE 6           MARKET SIZE VALIDATION FROM PRIMARY SOURCES  63

2.2.2      SEGMENTAL MARKET SIZE ESTIMATION           63

FIGURE 7           MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH       63

2.3         MARKET GROWTH RATE PROJECTIONS             65

FIGURE 8           CUSTOM ANTIBODY MARKET: CAGR PROJECTIONS      65

TABLE 1             IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS           66

2.4         MARKET BREAKDOWN AND DATA TRIANGULATION    67

FIGURE 9           DATA TRIANGULATION METHODOLOGY         67

2.5         RESEARCH ASSUMPTIONS         68

2.6         LIMITATIONS   68

2.7         RISK ANALYSIS 69

2.8         RECESSION IMPACT ANALYSIS 69

3            EXECUTIVE SUMMARY 71

FIGURE 10         CUSTOM ANTIBODY MARKET, BY SERVICE, 2024 VS. 2029 (USD MILLION)          71

FIGURE 11         CUSTOM ANTIBODY MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)          72

FIGURE 12         CUSTOM ANTIBODY MARKET, BY SOURCE, 2024 VS. 2029 (USD MILLION)          72

FIGURE 13         CUSTOM ANTIBODY MARKET, BY INDICATION, 2024 VS. 2029 (USD MILLION) 73

FIGURE 14         CUSTOM ANTIBODY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 73

FIGURE 15         GEOGRAPHICAL SNAPSHOT OF CUSTOM ANTIBODY MARKET              74

4            PREMIUM INSIGHTS      76

4.1         CUSTOM ANTIBODY MARKET OVERVIEW          76

FIGURE 16         GROWING IMPORTANCE OF CUSTOM ANTIBODIES IN PRECISION MEDICINE TO DRIVE GROWTH       76

4.2         ASIA PACIFIC: CUSTOM ANTIBODY MARKET,  BY SERVICE AND COUNTRY (2023)           77

FIGURE 17         ANTIBODY DEVELOPMENT SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC CUSTOM ANTIBODY MARKET IN 2023              77

4.3         CUSTOM ANTIBODY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES           78

FIGURE 18         CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD              78

4.4         CUSTOM ANTIBODY MARKET SHARE, BY END USER, 2023          78

FIGURE 19         PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2023     78

5            MARKET OVERVIEW     79

5.1         INTRODUCTION            79

5.2         MARKET DYNAMICS     79

FIGURE 20         CUSTOM ANTIBODY MARKET: DRIVERS, RESTRAINTS,  OPPORTUNITIES, AND CHALLENGES    79

TABLE 2             CUSTOM ANTIBODY MARKET: IMPACT ANALYSIS         80

5.2.1      DRIVERS            80

5.2.1.1   Growing importance of custom antibodies in precision medicine             80

5.2.1.2   Use of antibodies in biomarker identification and validation      81

5.2.1.3   Rising research activities and funding investments for antibody development              81

5.2.1.4   Advancements in biotechnology and genetic engineering           82

5.2.2      RESTRAINTS     83

5.2.2.1   High cost and time-consuming antibody development from transgenic animals              83

5.2.3      OPPORTUNITIES           83

5.2.3.1   Rising therapeutic and diagnostic application of antibodies        83

5.2.3.2   High scope for growth in emerging economies             84

5.2.4      CHALLENGES   84

5.2.4.1   Challenges associated with safety and stability             84

5.3         TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 85

FIGURE 21         TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES              85

5.4         REGULATORY LANDSCAPE       86

5.4.1      REGULATORY SCENARIO           86

5.4.2      REGULATORY BODIES, GOVERNMENT AGENCIES,  AND OTHER ORGANIZATIONS          86

TABLE 3             NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,  AND OTHER ORGANIZATIONS       86

TABLE 4             EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         87

TABLE 5             ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         89

TABLE 6             REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         91

5.5         VALUE CHAIN ANALYSIS            92

FIGURE 22         CUSTOM ANTIBODY MARKET: VALUE CHAIN ANALYSIS              92

5.6         TECHNOLOGICAL ANALYSIS    93

5.6.1      KEY TECHNOLOGIES    93

5.6.1.1   Hybridoma technology      93

5.6.1.2   Phage display technology   94

5.6.1.3   Recombinant DNA technology        94

5.6.2      COMPLIMENTARY TECHNOLOGIES      94

5.6.2.1   Next-generation sequencing            94

5.6.2.2   High-throughput screening              94

5.6.3      ADJACENT TECHNOLOGIES      95

5.6.3.1   Single-cell analysis technology         95

5.6.3.2   Peptide synthesis 95

5.6.3.3   Protein engineering           95

5.7         PRICING ANALYSIS        95

5.7.1      INDICATIVE PRICING ANALYSIS, BY SERVICE, 2023 & 2024           96

TABLE 7             INDICATIVE PRICE ANALYSIS, BY SERVICE, 2023 & 2024  96

5.7.2      INDICATIVE PRICING ANALYSIS, BY REGION, 2023 & 2024            96

TABLE 8             INDICATIVE PRICE ANALYSIS, BY REGION, 2023 & 2024  96

5.8         PATENT ANALYSIS        96

5.8.1      METHODOLOGY           96

5.8.2      PATENTS FILED, BY DOCUMENT TYPE, 2014–2024          96

TABLE 9             PATENTS FILED, 2014–2024        96

5.8.3      INNOVATION AND PATENT APPLICATIONS      97

FIGURE 23         TOTAL NUMBER OF PATENTS GRANTED, 2014–2024      97

5.8.4      TOP APPLICANTS          97

FIGURE 24         TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS,  2014–2024       97

TABLE 10           TOP 20 PATENT OWNERS IN CUSTOM ANTIBODY MARKET, 2014–2024          98

TABLE 11           INDICATIVE LIST OF PATENTS IN CUSTOM ANTIBODY MARKET, 2022–2024       99

5.9         SUPPLY CHAIN ANALYSIS          100

FIGURE 25         CUSTOM ANTIBODY MARKET: SUPPLY CHAIN ANALYSIS              101

5.10       ECOSYSTEM ANALYSIS 101

FIGURE 26         CUSTOM ANTIBODY MARKET: ECOSYSTEM ANALYSIS  101

5.10.1    CUSTOM ANTIBODY RAW MATERIAL SUPPLIERS           102

TABLE 12           CUSTOM ANTIBODY MARKET: RAW MATERIAL SUPPLIERS              102

5.10.2    CUSTOM ANTIBODY SERVICE PROVIDERS         102

TABLE 13           CUSTOM ANTIBODY MARKET: SERVICE PROVIDERS     102

5.10.3    CUSTOM ANTIBODY END USERS            102

TABLE 14           CUSTOM ANTIBODY MARKET: END USERS        103

5.10.4    CUSTOM ANTIBODY REGULATORY AUTHORITIES        103

TABLE 15           CUSTOM ANTIBODY MARKET: REGULATORY AUTHORITIES              103

5.11       KEY CONFERENCES AND EVENTS, 2024–2025     104

TABLE 16           CUSTOM ANTIBODY MARKET: LIST OF CONFERENCES AND EVENTS, 2024–2025        104

5.12       PORTER’S FIVE FORCES ANALYSIS         105

FIGURE 27         CUSTOM ANTIBODY MARKET: PORTER’S FIVE FORCES ANALYSIS          105

5.12.1    IMPACT OF PORTER’S FIVE FORCES ON CUSTOM ANTIBODY MARKET              105

TABLE 17           CUSTOM ANTIBODY MARKET: PORTER’S FIVE FORCES ANALYSIS          105

5.12.2    INTENSITY OF COMPETITIVE RIVALRY 106

5.12.3    BARGAINING POWER OF SUPPLIERS     106

5.12.4    BARGAINING POWER OF BUYERS           106

5.12.5    THREAT OF SUBSTITUTES         106

5.12.6    THREAT OF NEW ENTRANTS    106

5.13       KEY STAKEHOLDERS AND BUYING CRITERIA    107

5.13.1    KEY STAKEHOLDERS IN BUYING PROCESS         107

FIGURE 28         INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CUSTOM ANTIBODIES  107

5.13.2    CUSTOM ANTIBODY MARKET: BUYING CRITERIA FOR END USERS              108

FIGURE 29         KEY BUYING CRITERIA FOR END USERS OF CUSTOM ANTIBODIES     108

TABLE 18           BUYING CRITERIA FOR CUSTOM ANTIBODIES, BY END USER              108

5.14       INVESTMENT AND FUNDING SCENARIO            109

TABLE 19           RESEARCH FUNDING BY VARIOUS INSTITUTES/CENTERS, 2020–2024 (USD MILLION)          109

6            CUSTOM ANTIBODY MARKET, BY SERVICE        110

6.1         INTRODUCTION            111

TABLE 20           CUSTOM ANTIBODY MARKET, BY SERVICE, 2022–2029 (USD MILLION)          111

6.2         ANTIBODY DEVELOPMENT      111

TABLE 21           CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)     112

TABLE 22           CUSTOM ANTIBODY DEVELOPMENT MARKET, BY REGION, 2022–2029 (USD MILLION)          112

TABLE 23           NORTH AMERICA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      113

TABLE 24           EUROPE: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 113

TABLE 25           ASIA PACIFIC: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY COUNTRY,  2022–2029 (USD MILLION)         114

TABLE 26           LATIN AMERICA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      114

TABLE 27           MIDDLE EAST: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY COUNTRY,  2022–2029 (USD MILLION)         115

TABLE 28           GCC COUNTRIES: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      115

6.2.1      ANTIBODY CHARACTERIZATION           115

6.2.1.1   Growing adoption of therapeutic antibodies to drive growth      115

TABLE 29           ANTIBODY CHARACTERIZATION MARKET, BY REGION, 2022–2029 (USD MILLION)     116

TABLE 30           NORTH AMERICA: ANTIBODY CHARACTERIZATION MARKET, BY COUNTRY,  2022–2029 (USD MILLION)         116

TABLE 31           EUROPE: ANTIBODY CHARACTERIZATION MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 117

TABLE 32           ASIA PACIFIC: ANTIBODY CHARACTERIZATION MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 117

TABLE 33           LATIN AMERICA: ANTIBODY CHARACTERIZATION MARKET, BY COUNTRY,  2022–2029 (USD MILLION)         118

TABLE 34           MIDDLE EAST: ANTIBODY CHARACTERIZATION MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 118

TABLE 35           GCC COUNTRIES: ANTIBODY CHARACTERIZATION MARKET, BY COUNTRY,  2022–2029 (USD MILLION)         118

6.2.2      ANTIGEN PREPARATION           119

6.2.2.1   Rising use of research antibodies to support market growth       119

TABLE 36           ANTIGEN PREPARATION MARKET, BY REGION, 2022–2029 (USD MILLION)          120

TABLE 37           NORTH AMERICA: ANTIGEN PREPARATION MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 120

TABLE 38           EUROPE: ANTIGEN PREPARATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          121

TABLE 39           ASIA PACIFIC: ANTIGEN PREPARATION MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 121

TABLE 40           LATIN AMERICA: ANTIGEN PREPARATION MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 122

TABLE 41           MIDDLE EAST: ANTIGEN PREPARATION MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 122

TABLE 42           GCC COUNTRIES: ANTIGEN PREPARATION MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 122

6.2.3      IMMUNIZATION & HYBRIDOMA PRODUCTION 123

6.2.3.1   Rising demand for therapeutic antibodies to drive market          123

TABLE 43           IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY REGION,  2022–2029 (USD MILLION)     123

TABLE 44           NORTH AMERICA: IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          124

TABLE 45           EUROPE: IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      124

TABLE 46           ASIA PACIFIC: IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)         125

TABLE 47           LATIN AMERICA: IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          125

TABLE 48           MIDDLE EAST: IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)         126

TABLE 49           GCC COUNTRIES: IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          126

6.3         ANTIBODY PRODUCTION & PURIFICATION      126

6.3.1      RESEARCH & DEVELOPMENT IN LIFE SCIENCES TO BOOST MARKET GROWTH          126

TABLE 50          CUSTOM ANTIBODY PRODUCTION & PURIFICATION MARKET, BY REGION,  2022–2029 (USD MILLION)             127

TABLE 51           NORTH AMERICA: CUSTOM ANTIBODY PRODUCTION & PURIFICATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)         127

TABLE 52           EUROPE: CUSTOM ANTIBODY PRODUCTION & PURIFICATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)         128

TABLE 53           ASIA PACIFIC: CUSTOM ANTIBODY PRODUCTION & PURIFICATION MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      128

TABLE 54           LATIN AMERICA: CUSTOM ANTIBODY PRODUCTION & PURIFICATION MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)      129

TABLE 55           MIDDLE EAST: CUSTOM ANTIBODY PRODUCTION & PURIFICATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)         129

TABLE 56           GCC COUNTRIES: CUSTOM ANTIBODY PRODUCTION & PURIFICATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)         129

6.4         ANTIBODY FRAGMENTATION & LABELING       130

6.4.1      RISING RESEARCH AND CLINICAL APPLICATIONS TO DRIVE GROWTH              130

TABLE 57           CUSTOM ANTIBODY FRAGMENTATION & LABELING MARKET, BY REGION,  2022–2029 (USD MILLION)             131

TABLE 58           NORTH AMERICA: CUSTOM ANTIBODY FRAGMENTATION & LABELING MARKET,  BY COUNTRY, 2022–2029 (USD MILLION) 131

TABLE 59           EUROPE: CUSTOM ANTIBODY FRAGMENTATION & LABELING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)         132

TABLE 60           ASIA PACIFIC: CUSTOM ANTIBODY FRAGMENTATION & LABELING MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 132

TABLE 61           LATIN AMERICA: CUSTOM ANTIBODY FRAGMENTATION & LABELING MARKET,  BY COUNTRY, 2022–2029 (USD MILLION) 133

TABLE 62           MIDDLE EAST: CUSTOM ANTIBODY FRAGMENTATION & LABELING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)   133

TABLE 63           GCC COUNTRIES: CUSTOM ANTIBODY FRAGMENTATION & LABELING MARKET,  BY COUNTRY, 2022–2029 (USD MILLION) 133

7            CUSTOM ANTIBODY MARKET, BY TYPE             134

7.1         INTRODUCTION            135

TABLE 64           CUSTOM ANTIBODY MARKET, BY TYPE, 2022–2029 (USD MILLION)          135

7.2         MONOCLONAL ANTIBODIES    135

7.2.1      HIGH DEGREE OF SENSITIVITY AND PRECISION TO BOOST MARKET GROWTH          135

TABLE 65           CUSTOM MONOCLONAL ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION)          136

TABLE 66           NORTH AMERICA: CUSTOM MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      136

TABLE 67           EUROPE: CUSTOM MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 137

TABLE 68           ASIA PACIFIC: CUSTOM MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)         137

TABLE 69           LATIN AMERICA: CUSTOM MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      138

TABLE 70          MIDDLE EAST: CUSTOM MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)         138

TABLE 71           GCC COUNTRIES: CUSTOM MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      138

7.3         POLYCLONAL ANTIBODIES       139

7.3.1      VERSATILITY AND EFFICACY IN RECOGNITION OF ANTIGEN SITES TO BOOST MARKET GROWTH        139

TABLE 72           CUSTOM POLYCLONAL ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION)          140

TABLE 73           NORTH AMERICA: CUSTOM POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      140

TABLE 74           EUROPE: CUSTOM POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 141

TABLE 75           ASIA PACIFIC: CUSTOM POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)         141

TABLE 76           LATIN AMERICA: CUSTOM POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      142

TABLE 77           MIDDLE EAST: CUSTOM POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)         142

TABLE 78           GCC COUNTRIES: CUSTOM POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      142

7.4         RECOMBINANT ANTIBODIES    143

7.4.1      RISING RESEARCH & DEVELOPMENT IN LIFE SCIENCES INDUSTRY TO BOOST MARKET GROWTH        143

TABLE 79           CUSTOM RECOMBINANT ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION)          144

TABLE 80           NORTH AMERICA: CUSTOM RECOMBINANT ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      144

TABLE 81           EUROPE: CUSTOM RECOMBINANT ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    145

TABLE 82           ASIA PACIFIC: CUSTOM RECOMBINANT ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)         145

TABLE 83           LATIN AMERICA: CUSTOM RECOMBINANT ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      146

TABLE 84           MIDDLE EAST: CUSTOM RECOMBINANT ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      146

TABLE 85           GCC COUNTRIES: CUSTOM RECOMBINANT ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      146

7.5         OTHER CUSTOM ANTIBODIES  147

TABLE 86           OTHER CUSTOM ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION) 147

TABLE 87           NORTH AMERICA: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 148

TABLE 88           EUROPE: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 148

TABLE 89           ASIA PACIFIC: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 149

TABLE 90           LATIN AMERICA: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 149

TABLE 91           MIDDLE EAST: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 150

TABLE 92           GCC COUNTRIES: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 150

8            CUSTOM ANTIBODY MARKET, BY SOURCE        151

8.1         INTRODUCTION            152

TABLE 93           CUSTOM ANTIBODY MARKET, BY SOURCE, 2022–2029 (USD MILLION)          152

8.2         MICE    152

8.2.1      WIDESPREAD AVAILABILITY AND COST-EFFECTIVENESS  TO PROPEL MARKET            152

TABLE 94           CUSTOM ANTIBODY MARKET FOR MICE, BY REGION, 2022–2029 (USD MILLION)     153

TABLE 95           NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY,  2022–2029 (USD MILLION) 153

TABLE 96           EUROPE: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY,  2022–2029 (USD MILLION) 154

TABLE 97           ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY,  2022–2029 (USD MILLION) 154

TABLE 98           LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY,  2022–2029 (USD MILLION) 155

TABLE 99           MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY,  2022–2029 (USD MILLION) 155

TABLE 100         GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY,  2022–2029 (USD MILLION) 155

8.3         RABBITS            156

8.3.1      ABILITY TO GENERATE HIGH ANTIBODY DIVERSITY WITH OPTIMAL AFFINITY TO DRIVE MARKET    156

TABLE 101         CUSTOM ANTIBODY MARKET FOR RABBITS, BY REGION, 2022–2029 (USD MILLION)     156

TABLE 102        NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY,  2022–2029 (USD MILLION)         157

TABLE 103         EUROPE: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY,  2022–2029 (USD MILLION) 157

TABLE 104         ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY,  2022–2029 (USD MILLION) 158

TABLE 105         LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2022–2029 (USD MILLION)            158

TABLE 106         MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY,  2022–2029 (USD MILLION) 159

TABLE 107         GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY,  2022–2029 (USD MILLION)         159

8.4         OTHER SOURCES           159

TABLE 108         CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY REGION,  2022–2029 (USD MILLION)     160

TABLE 109         NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2022–2029 (USD MILLION)       161

TABLE 110         EUROPE: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY,  2022–2029 (USD MILLION)         161

TABLE 111         ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY,  2022–2029 (USD MILLION)     162

TABLE 112         LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2022–2029 (USD MILLION)       162

TABLE 113         MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY,  2022–2029 (USD MILLION)     162

TABLE 114         GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2022–2029 (USD MILLION)       163

9            CUSTOM ANTIBODY MARKET, BY APPLICATION           164

9.1         INTRODUCTION            165

TABLE 115         CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 165

9.2         RESEARCH        165

9.2.1      HIGH DEGREE OF SENSITIVITY AND SPECIFICITY TO BOOST MARKET GROWTH          165

TABLE 116         CUSTOM ANTIBODY MARKET FOR RESEARCH APPLICATIONS, BY REGION,  2022–2029 (USD MILLION)             166

TABLE 117         NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR RESEARCH APPLICATIONS,  BY COUNTRY, 2022–2029 (USD MILLION)  166

TABLE 118         EUROPE: CUSTOM ANTIBODY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)           167

TABLE 119         ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)           167

TABLE 120         LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR RESEARCH APPLICATIONS,  BY COUNTRY, 2022–2029 (USD MILLION)  168

TABLE 121         MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)           168

TABLE 122         GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR RESEARCH APPLICATIONS,  BY COUNTRY, 2022–2029 (USD MILLION)  168

9.3         THERAPEUTIC 169

9.3.1      RISING DEMAND FOR ANTIBODY-BASED THERAPEUTICS TO SUPPORT MARKET GROWTH    169

TABLE 123         CUSTOM ANTIBODY MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION,  2022–2029 (USD MILLION)            169

TABLE 124         NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)              170

TABLE 125         EUROPE: CUSTOM ANTIBODY MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)           170

TABLE 126         ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)              171

TABLE 127         LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR THERAPEUTIC APPLICATIONS,  BY COUNTRY, 2022–2029 (USD MILLION)              171

TABLE 128         MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR THERAPEUTIC APPLICATIONS,  BY COUNTRY, 2022–2029 (USD MILLION)              172

TABLE 129         GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR THERAPEUTIC APPLICATIONS,  BY COUNTRY, 2022–2029 (USD MILLION)              172

10          CUSTOM ANTIBODY MARKET, BY INDICATION 173

10.1       INTRODUCTION            174

TABLE 130         CUSTOM ANTIBODY MARKET, BY INDICATION, 2022–2029 (USD MILLION) 174

10.2       ONCOLOGY      174

10.2.1    RISING PREVALENCE OF CANCER TO DRIVE MARKET   174

TABLE 131         CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY REGION, 2022–2029 (USD MILLION)          175

TABLE 132         NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)  175

TABLE 133         EUROPE: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY,  2022–2029 (USD MILLION) 176

TABLE 134         ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)         176

TABLE 135         LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)  177

TABLE 136        MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)         177

TABLE 137         GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY,  2022–2029 (USD MILLION) 177

10.3       INFECTIOUS DISEASES 178

10.3.1    USE OF ANTIBODIES IN VACCINE & THERAPEUTIC DEVELOPMENT TO BOOST MARKET GROWTH        178

TABLE 138         CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY REGION,  2022–2029 (USD MILLION)     178

TABLE 139         NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)            179

TABLE 140         EUROPE: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,  2022–2029 (USD MILLION)     179

TABLE 141         ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)       180

TABLE 142         LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)            180

TABLE 143         MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)            181

TABLE 144         GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)            181

10.4       IMMUNOLOGY 181

10.4.1    RISING NUMBER OF PRODUCTS UNDER CLINICAL STUDIES TO BOOST MARKET GROWTH        181

TABLE 145        CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY REGION, 2022–2029 (USD MILLION)          182

TABLE 146         NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)         183

TABLE 147         EUROPE: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)         183

TABLE 148         ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)         184

TABLE 149         LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)         184

TABLE 150         MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)         185

TABLE 151         GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)         185

10.5       NEUROBIOLOGY           185

10.5.1    RISING DEMAND FOR ANTIBODIES IN NEURODEGENERATIVE DISEASES TO PROPEL MARKET 185

TABLE 152         CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY REGION,  2022–2029 (USD MILLION)     186

TABLE 153         NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)        186

TABLE 154         EUROPE: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)         187

TABLE 155         ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)     187

TABLE 156         LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)     188

TABLE 157         MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)     188

TABLE 158         GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)        188

10.6       CARDIOVASCULAR DISEASES   189

10.6.1    RISING DEMAND FOR CVD BIOMARKERS TO DRIVE MARKET    189

TABLE 159         CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION,  2022–2029 (USD MILLION)        189

TABLE 160         NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES,  BY COUNTRY, 2022–2029 (USD MILLION)              190

TABLE 161         EUROPE: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES,  BY COUNTRY, 2022–2029 (USD MILLION)              190

TABLE 162         ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES,  BY COUNTRY, 2022–2029 (USD MILLION)              191

TABLE 163         LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES,  BY COUNTRY, 2022–2029 (USD MILLION)              191

TABLE 164         MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES,  BY COUNTRY, 2022–2029 (USD MILLION)              192

TABLE 165         GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES,  BY COUNTRY, 2022–2029 (USD MILLION)              192

10.7       OTHER INDICATIONS   192

TABLE 166         CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY REGION,  2022–2029 (USD MILLION)     193

TABLE 167         NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)             194

TABLE 168         EUROPE: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY,  2022–2029 (USD MILLION)           194

TABLE 169         ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY,  2022–2029 (USD MILLION)           195

TABLE 170         LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)             195

TABLE 171         MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)             196

TABLE 172         GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)             196

11          CUSTOM ANTIBODY MARKET, BY END USER     197

11.1       INTRODUCTION            198

TABLE 173         CUSTOM ANTIBODY MARKET, BY END USER, 2022–2029 (USD MILLION)          198

11.2       PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES   198

11.2.1    RISING DEMAND FOR THERAPEUTIC ANTIBODIES TO BOOST MARKET GROWTH          198

TABLE 174         CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES,  BY REGION, 2022–2029 (USD MILLION)              199

TABLE 175         NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 199

TABLE 176         EUROPE: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 200

TABLE 177         ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 200

TABLE 178         LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 201

TABLE 179         MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 201

TABLE 180         GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 201

11.3       ACADEMIC & RESEARCH INSTITUTES   202

11.3.1    GROWING INDUSTRY-ACADEMIA COLLABORATIONS TO DRIVE MARKET            202

TABLE 181         CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION)      202

TABLE 182         NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)              203

TABLE 183         EUROPE: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)          203

TABLE 184         ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES,  BY COUNTRY, 2022–2029 (USD MILLION)        204

TABLE 185         LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)              204

TABLE 186         MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES,  BY COUNTRY, 2022–2029 (USD MILLION)    205

TABLE 187         GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)              205

11.4       CONTRACT RESEARCH ORGANIZATIONS          205

11.4.1    INCREASING DEMAND FOR MABS AND ADC SERVICES  TO PROPEL MARKET            205

TABLE 188         CUSTOM ANTIBODY MARKET FOR CROS, BY REGION, 2022–2029 (USD MILLION)     206

TABLE 189         NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR CROS, BY COUNTRY,  2022–2029 (USD MILLION) 206

TABLE 190         EUROPE: CUSTOM ANTIBODY MARKET FOR CROS, BY COUNTRY,  2022–2029 (USD MILLION) 207

TABLE 191         ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR CROS, BY COUNTRY,  2022–2029 (USD MILLION) 207

TABLE 192         LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR CROS, BY COUNTRY,  2022–2029 (USD MILLION) 208

TABLE 193         MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR CROS, BY COUNTRY,  2022–2029 (USD MILLION) 208

TABLE 194         GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR CROS, BY COUNTRY,  2022–2029 (USD MILLION) 208

12          CUSTOM ANTIBODY MARKET, BY REGION        209

12.1       INTRODUCTION            210

TABLE 195         CUSTOM ANTIBODY MARKET, BY REGION, 2022–2029 (USD MILLION)          210

12.2       NORTH AMERICA          210

FIGURE 30         NORTH AMERICA: CUSTOM ANTIBODY MARKET SNAPSHOT              211

TABLE 196         NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 212

TABLE 197         NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022–2029 (USD MILLION)          212

TABLE 198         NORTH AMERICA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE,  2022–2029 (USD MILLION) 212

TABLE 199         NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY TYPE, 2022–2029 (USD MILLION)          213

TABLE 200         NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022–2029 (USD MILLION)          213

TABLE 201         NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY APPLICATION,  2022–2029 (USD MILLION)        213

TABLE 202         NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022–2029 (USD MILLION)             214

TABLE 203         NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY END USER,  2022–2029 (USD MILLION)          214

12.2.1    US         214

12.2.1.1 Growing number of FDA approvals for monoclonal antibody therapies to drive market   214

FIGURE 31         NIH FUNDING IN LAST 10 YEARS FOR HEALTHCARE R&D (2014–2024)    215

TABLE 204         US: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022–2029 (USD MILLION)          216

TABLE 205         US: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)          216

TABLE 206         US: CUSTOM ANTIBODY MARKET, BY TYPE, 2022–2029 (USD MILLION)          216

TABLE 207         US: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022–2029 (USD MILLION)          217

TABLE 208         US: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 217

TABLE 209         US: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022–2029 (USD MILLION) 217

TABLE 210         US: CUSTOM ANTIBODY MARKET, BY END USER, 2022–2029 (USD MILLION) 218

12.2.2    CANADA            218

12.2.2.1 Increasing incidence of cancer to support market growth           218

TABLE 211         CANADA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022–2029 (USD MILLION)     219

TABLE 212         CANADA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE,  2022–2029 (USD MILLION)          219

TABLE 213         CANADA: CUSTOM ANTIBODY MARKET, BY TYPE, 2022–2029 (USD MILLION) 220

TABLE 214         CANADA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022–2029 (USD MILLION)     220

TABLE 215         CANADA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)          220

TABLE 216         CANADA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022–2029 (USD MILLION)          221

TABLE 217         CANADA: CUSTOM ANTIBODY MARKET, BY END USER, 2022–2029 (USD MILLION)     221

12.2.3    NORTH AMERICA: RECESSION IMPACT 221

12.3       EUROPE             222

TABLE 218         EUROPE: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     222

TABLE 219         EUROPE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022–2029 (USD MILLION) 223

TABLE 220         EUROPE: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE,  2022–2029 (USD MILLION)          223

TABLE 221         EUROPE: CUSTOM ANTIBODY MARKET, BY TYPE, 2022–2029 (USD MILLION) 224

TABLE 222         EUROPE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022–2029 (USD MILLION) 224

TABLE 223         EUROPE: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)          224

TABLE 224         EUROPE: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022–2029 (USD MILLION)     225

TABLE 225         EUROPE: CUSTOM ANTIBODY MARKET, BY END USER, 2022–2029 (USD MILLION)     225

12.3.1    GERMANY         225

12.3.1.1 Growing investment in ADCs development to drive market       225

TABLE 226         GERMANY: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022–2029 (USD MILLION)     226

TABLE 227         GERMANY: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE,  2022–2029 (USD MILLION)          226

TABLE 228         GERMANY: CUSTOM ANTIBODY MARKET, BY TYPE, 2022–2029 (USD MILLION) 227

TABLE 229         GERMANY: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022–2029 (USD MILLION)     227

TABLE 230         GERMANY: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)          227

TABLE 231         GERMANY: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022–2029 (USD MILLION)          228

TABLE 232         GERMANY: CUSTOM ANTIBODY MARKET, BY END USER, 2022–2029 (USD MILLION)     228

12.3.2    UK         228

12.3.2.1 Life sciences funding with biotech firms to boost adoption of custom antibodies              228

TABLE 233         UK: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022–2029 (USD MILLION)          229

TABLE 234         UK: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)          229

TABLE 235         UK: CUSTOM ANTIBODY MARKET, BY TYPE, 2022–2029 (USD MILLION)          230

TABLE 236         UK CUSTOM ANTIBODY MARKET, BY SOURCE, 2022–2029 (USD MILLION)          230

TABLE 237         UK: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 230

TABLE 238         UK: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022–2029 (USD MILLION) 231

TABLE 239         UK: CUSTOM ANTIBODY MARKET, BY END USER, 2022–2029 (USD MILLION) 231

12.3.3    FRANCE             231

12.3.3.1 Increasing government investments in pharmaceutical industry to drive growth              231

TABLE 240         FRANCE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022–2029 (USD MILLION) 232

TABLE 241         FRANCE: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE,  2022–2029 (USD MILLION)          233

TABLE 242         FRANCE: CUSTOM ANTIBODY MARKET, BY TYPE, 2022–2029 (USD MILLION) 233

TABLE 243         FRANCE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022–2029 (USD MILLION) 233

TABLE 244         FRANCE: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)          234

TABLE 245         FRANCE: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022–2029 (USD MILLION)     234

TABLE 246         FRANCE: CUSTOM ANTIBODY MARKET, BY END USER, 2022–2029 (USD MILLION)     234

12.3.4    ITALY   235

12.3.4.1 Rising research activities in pharma R&D to boost market growth            235

TABLE 247         ITALY: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022–2029 (USD MILLION) 235

TABLE 248         ITALY: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)             236

TABLE 249         ITALY: CUSTOM ANTIBODY MARKET, BY TYPE, 2022–2029 (USD MILLION)          236

TABLE 250         ITALY: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022–2029 (USD MILLION) 236

TABLE 251         ITALY: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)     237

TABLE 252         ITALY: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022–2029 (USD MILLION)     237

TABLE 253         ITALY: CUSTOM ANTIBODY MARKET, BY END USER, 2022–2029 (USD MILLION) 237

12.3.5    SPAIN   238

12.3.5.1 Growing focus on advancements in personalized medicine to support market growth   238

TABLE 254         SPAIN: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022–2029 (USD MILLION) 239

TABLE 255         SPAIN: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE,  2022–2029 (USD MILLION)          239

TABLE 256         SPAIN: CUSTOM ANTIBODY MARKET, BY TYPE, 2022–2029 (USD MILLION)          240

TABLE 257         SPAIN: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022–2029 (USD MILLION) 240

TABLE 258         SPAIN: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)     240

TABLE 259         SPAIN: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022–2029 (USD MILLION)     241

TABLE 260         SPAIN: CUSTOM ANTIBODY MARKET, BY END USER, 2022–2029 (USD MILLION) 241

12.3.6    REST OF EUROPE           241

TABLE 261         REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022–2029 (USD MILLION)          242

TABLE 262         REST OF EUROPE: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE,  2022–2029 (USD MILLION) 243

TABLE 263         REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY TYPE, 2022–2029 (USD MILLION)          243

TABLE 264         REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022–2029 (USD MILLION)          243

TABLE 265         REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)           244

TABLE 266         REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY INDICATION,  2022–2029 (USD MILLION)           244

TABLE 267        REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY END USER, 2022–2029 (USD MILLION)          245

12.3.7    EUROPE: RECESSION IMPACT   245

12.4       ASIA PACIFIC    245

FIGURE 32         ASIA PACIFIC: CUSTOM ANTIBODY MARKET SNAPSHOT              246

TABLE 268         ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          247

TABLE 269         ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022–2029 (USD MILLION)          247

TABLE 270         ASIA PACIFIC: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE,  2022–2029 (USD MILLION)    248

TABLE 271         ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY TYPE, 2022–2029 (USD MILLION)     248

TABLE 272         ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022–2029 (USD MILLION)          248

TABLE 273        ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY APPLICATION,  2022–2029 (USD MILLION)          249

TABLE 274         ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022–2029 (USD MILLION)          249

TABLE 275         ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY END USER, 2022–2029 (USD MILLION)          249

12.4.1    CHINA  250

12.4.1.1 Rising prevalence of cardiovascular diseases and cancer to support market growth              250

TABLE 276         CHINA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022–2029 (USD MILLION) 250

TABLE 277         CHINA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE,  2022–2029 (USD MILLION)          251

TABLE 278         CHINA: CUSTOM ANTIBODY MARKET, BY TYPE, 2022–2029 (USD MILLION) 251

TABLE 279         CHINA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022–2029 (USD MILLION) 251

TABLE 280         CHINA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)     252

TABLE 281         CHINA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022–2029 (USD MILLION)     252

TABLE 282         CHINA: CUSTOM ANTIBODY MARKET, BY END USER, 2022–2029 (USD MILLION) 252

12.4.2    JAPAN  253

12.4.2.1 Increasing research activities for development of ADCs to drive market   253

TABLE 283         JAPAN: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022–2029 (USD MILLION) 253

TABLE 284         JAPAN: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE,  2022–2029 (USD MILLION)          254

TABLE 285         JAPAN: CUSTOM ANTIBODY MARKET, BY TYPE, 2022–2029 (USD MILLION) 254

TABLE 286         JAPAN: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022–2029 (USD MILLION) 254

TABLE 287         JAPAN: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)     255

TABLE 288         JAPAN: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022–2029 (USD MILLION)     255

TABLE 289         JAPAN: CUSTOM ANTIBODY MARKET, BY END USER, 2022–2029 (USD MILLION) 255

12.4.3    INDIA   256

12.4.3.1 Favorable scenario for foreign direct investment to propel market            256

TABLE 290         INDIA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022–2029 (USD MILLION) 256

TABLE 291         INDIA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)             257

TABLE 292         INDIA: CUSTOM ANTIBODY MARKET, BY TYPE, 2022–2029 (USD MILLION)          257

TABLE 293         INDIA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022–2029 (USD MILLION) 257

TABLE 294         INDIA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)     258

TABLE 295         INDIA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022–2029 (USD MILLION)     258

TABLE 296         INDIA: CUSTOM ANTIBODY MARKET, BY END USER, 2022–2029 (USD MILLION) 258

12.4.4    SOUTH KOREA 259

12.4.4.1 Increased research & development of drugs to support market growth     259

TABLE 297         SOUTH KOREA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022–2029 (USD MILLION)          259

TABLE 298        SOUTH KOREA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE,  2022–2029 (USD MILLION)    260

TABLE 299         SOUTH KOREA: CUSTOM ANTIBODY MARKET, BY TYPE, 2022–2029 (USD MILLION)     260

TABLE 300         SOUTH KOREA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022–2029 (USD MILLION)          260

TABLE 301         SOUTH KOREA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)           261

TABLE 302         SOUTH KOREA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022–2029 (USD MILLION)             261

TABLE 303         SOUTH KOREA: CUSTOM ANTIBODY MARKET, BY END USER, 2022–2029 (USD MILLION)          261

12.4.5    AUSTRALIA       262

12.4.5.1 Increasing demand for innovative research solutions to propel market     262

TABLE 304         AUSTRALIA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022–2029 (USD MILLION)     263

TABLE 305         AUSTRALIA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE,  2022–2029 (USD MILLION)          263

TABLE 306         AUSTRALIA: CUSTOM ANTIBODY MARKET, BY TYPE, 2022–2029 (USD MILLION) 264

TABLE 307         AUSTRALIA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022–2029 (USD MILLION)     264

TABLE 308         AUSTRALIA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)          264

TABLE 309         AUSTRALIA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022–2029 (USD MILLION)          265

TABLE 310         AUSTRALIA: CUSTOM ANTIBODY MARKET, BY END USER, 2022–2029 (USD MILLION)          265

12.4.6    REST OF ASIA PACIFIC  265

TABLE 311         REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY SERVICE,  2022–2029 (USD MILLION)    266

TABLE 312         REST OF ASIA PACIFIC: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE,  2022–2029 (USD MILLION) 267

TABLE 313        REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY TYPE,  2022–2029 (USD MILLION)          267

TABLE 314         REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY SOURCE,  2022–2029 (USD MILLION)    268

TABLE 315         REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY APPLICATION,  2022–2029 (USD MILLION)        268

TABLE 316         REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY INDICATION,  2022–2029 (USD MILLION)           269

TABLE 317         REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY END USER,  2022–2029 (USD MILLION)          269

12.4.7    ASIA PACIFIC: RECESSION IMPACT        269

12.5       LATIN AMERICA             270

TABLE 318         LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          270

TABLE 319         LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022–2029 (USD MILLION)          271

TABLE 320         LATIN AMERICA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE,  2022–2029 (USD MILLION) 271

TABLE 321         LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY TYPE, 2022–2029 (USD MILLION)          272

TABLE 322         LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022–2029 (USD MILLION)          272

TABLE 323         LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY APPLICATION,  2022–2029 (USD MILLION)        272

TABLE 324         LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY INDICATION,  2022–2029 (USD MILLION)           273

TABLE 325         LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY END USER, 2022–2029 (USD MILLION)          273

12.5.1    BRAZIL 273

12.5.1.1 Increased government investments in pharmaceutical R&D to drive market              273

TABLE 326         BRAZIL: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022–2029 (USD MILLION) 274

TABLE 327         BRAZIL: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE,  2022–2029 (USD MILLION)          274

TABLE 328         BRAZIL: CUSTOM ANTIBODY MARKET, BY TYPE, 2022–2029 (USD MILLION) 275

TABLE 329         BRAZIL: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022–2029 (USD MILLION) 275

TABLE 330         BRAZIL: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)          275

TABLE 331         BRAZIL: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022–2029 (USD MILLION)     276

TABLE 332         BRAZIL: CUSTOM ANTIBODY MARKET, BY END USER, 2022–2029 (USD MILLION)     276

12.5.2    MEXICO             276

12.5.2.1 Rising demand for chronic disease treatment to support market growth   276

TABLE 333         MEXICO: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022–2029 (USD MILLION) 277

TABLE 334         MEXICO: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE,  2022–2029 (USD MILLION)          277

TABLE 335         MEXICO: CUSTOM ANTIBODY MARKET, BY TYPE, 2022–2029 (USD MILLION) 278

TABLE 336         MEXICO: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022–2029 (USD MILLION) 278

TABLE 337         MEXICO: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)          278

TABLE 338         MEXICO: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022–2029 (USD MILLION)     279

TABLE 339         MEXICO: CUSTOM ANTIBODY MARKET, BY END USER, 2022–2029 (USD MILLION)     279

12.5.3    REST OF LATIN AMERICA          279

TABLE 340         REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY SERVICE,  2022–2029 (USD MILLION)    280

TABLE 341         REST OF LATIN AMERICA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE,  2022–2029 (USD MILLION) 280

TABLE 342         REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY TYPE,  2022–2029 (USD MILLION)          281

TABLE 343         REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY SOURCE,  2022–2029 (USD MILLION)    281

TABLE 344         REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY APPLICATION,  2022–2029 (USD MILLION)        281

TABLE 345         REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY INDICATION,  2022–2029 (USD MILLION)           282

TABLE 346         REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY END USER, 2022–2029 (USD MILLION)    282

12.5.4    LATIN AMERICA: RECESSION IMPACT   282

12.6       MIDDLE EAST  283

TABLE 347         MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          283

TABLE 348         MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022–2029 (USD MILLION)          283

TABLE 349         MIDDLE EAST: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE,  2022–2029 (USD MILLION)    284

TABLE 350         MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY TYPE, 2022–2029 (USD MILLION)     284

TABLE 351         MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022–2029 (USD MILLION)          284

TABLE 352         MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY APPLICATION,  2022–2029 (USD MILLION)        285

TABLE 353         MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022–2029 (USD MILLION)          285

TABLE 354         MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY END USER, 2022–2029 (USD MILLION)          285

12.6.1    GCC COUNTRIES           286

TABLE 355        GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          286

TABLE 356         GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022–2029 (USD MILLION)          286

TABLE 357         GCC COUNTRIES: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)    287

TABLE 358         GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY TYPE, 2022–2029 (USD MILLION)          287

TABLE 359         GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022–2029 (USD MILLION)          287

TABLE 360         GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY APPLICATION,  2022–2029 (USD MILLION)        288

TABLE 361         GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY INDICATION,  2022–2029 (USD MILLION)           288

TABLE 362        GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY END USER,  2022–2029 (USD MILLION)          289

12.6.1.1 Saudi Arabia        289

12.6.1.1.1            Growing healthcare expenditure to boost market growth            289

TABLE 363         SAUDI ARABIA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022–2029 (USD MILLION)          290

TABLE 364         SAUDI ARABIA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE,  2022–2029 (USD MILLION)    290

TABLE 365         SAUDI ARABIA: CUSTOM ANTIBODY MARKET, BY TYPE, 2022–2029 (USD MILLION)     291

TABLE 366         SAUDI ARABIA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022–2029 (USD MILLION)          291

TABLE 367         SAUDI ARABIA: CUSTOM ANTIBODY MARKET, BY APPLICATION,  2022–2029 (USD MILLION)        291

TABLE 368        SAUDI ARABIA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022–2029 (USD MILLION)          292

TABLE 369         SAUDI ARABIA: CUSTOM ANTIBODY MARKET, BY END USER, 2022–2029 (USD MILLION)          292

12.6.1.2 UAE      292

12.6.1.2.1            Rising government funding to propel market 292

TABLE 370         UAE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022–2029 (USD MILLION) 293

TABLE 371         UAE: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)          293

TABLE 372         UAE: CUSTOM ANTIBODY MARKET, BY TYPE, 2022–2029 (USD MILLION)          294

TABLE 373         UAE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022–2029 (USD MILLION) 294

TABLE 374         UAE: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)     294

TABLE 375         UAE: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022–2029 (USD MILLION) 295

TABLE 376         UAE: CUSTOM ANTIBODY MARKET, BY END USER, 2022–2029 (USD MILLION) 295

12.6.1.3 Rest of GCC countries       295

TABLE 377         REST OF GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY SERVICE,  2022–2029 (USD MILLION)    296

TABLE 378         REST OF GCC COUNTRIES: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE,  2022–2029 (USD MILLION) 297

TABLE 379         REST OF GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY TYPE,  2022–2029 (USD MILLION)          297

TABLE 380         REST OF GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY SOURCE,  2022–2029 (USD MILLION)    298

TABLE 381         REST OF GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY APPLICATION,  2022–2029 (USD MILLION)        298

TABLE 382         REST OF GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY INDICATION,  2022–2029 (USD MILLION)           299

TABLE 383         REST OF GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY END USER,  2022–2029 (USD MILLION) 299

12.6.2    REST OF MIDDLE EAST 299

TABLE 384         REST OF MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY SERVICE,  2022–2029 (USD MILLION)    301

TABLE 385         REST OF MIDDLE EAST: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE,  2022–2029 (USD MILLION) 301

TABLE 386         REST OF MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY TYPE,  2022–2029 (USD MILLION)          302

TABLE 387         REST OF MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY SOURCE,  2022–2029 (USD MILLION)    302

TABLE 388         REST OF MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY APPLICATION,  2022–2029 (USD MILLION)        302

TABLE 389         REST OF MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY INDICATION,  2022–2029 (USD MILLION)           303

TABLE 390         REST OF MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY END USER,  2022–2029 (USD MILLION)          303

12.6.3    MIDDLE EAST: RECESSION IMPACT       303

12.7       AFRICA 304

12.7.1    GROWING MARKET FOR PHARMACEUTICALS AND INCREASING DEMAND FOR DRUGS TO SUPPORT MARKET GROWTH             304

TABLE 391         AFRICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022–2029 (USD MILLION) 304

TABLE 392         AFRICA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE,  2022–2029 (USD MILLION)          305

TABLE 393         AFRICA: CUSTOM ANTIBODY MARKET, BY TYPE, 2022–2029 (USD MILLION) 305

TABLE 394         AFRICA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022–2029 (USD MILLION) 305

TABLE 395         AFRICA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)          306

TABLE 396         AFRICA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022–2029 (USD MILLION)     306

TABLE 397         AFRICA: CUSTOM ANTIBODY MARKET, BY END USER, 2022–2029 (USD MILLION)     306

13          COMPETITIVE LANDSCAPE       308

13.1       INTRODUCTION            308

13.2       STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN           308

TABLE 398         OVERVIEW OF STRATEGIES ADOPTED BY KEY CUSTOM ANTIBODY COMPANIES             308

13.3       REVENUE ANALYSIS      310

FIGURE 33         REVENUE ANALYSIS OF KEY PLAYERS IN CUSTOM ANTIBODY MARKET,  2019–2023 (USD BILLION)     310

13.4       MARKET SHARE ANALYSIS         311

FIGURE 34         CUSTOM ANTIBODY MARKET SHARE ANALYSIS, BY KEY PLAYER (2023)  311

TABLE 399         CUSTOM ANTIBODY MARKET: DEGREE OF COMPETITION              311

13.5       BRAND/SERVICE COMPARATIVE ANALYSIS       313

FIGURE 35         BRAND/SERVICE COMPARATIVE ANALYSIS       313

13.5.1    THERMO FISHER SCIENTIFIC INC.          314

13.5.2    GENSCRIPT       314

13.5.3    BIO-RAD LABORATORIES, INC. 314

13.5.4    MERCK KGAA   314

13.5.5    AGILENT TECHNOLOGIES, INC.             314

13.6       COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023   314

13.6.1    STARS  315

13.6.2    EMERGING LEADERS    315

13.6.3    PERVASIVE PLAYERS     315

13.6.4    PARTICIPANTS 315

FIGURE 36         CUSTOM ANTIBODY MARKET: COMPANY EVALUATION  MATRIX (KEY PLAYERS), 2023    316

13.6.5    COMPANY FOOTPRINT: KEY PLAYERS, 2023      317

FIGURE 37         CUSTOM ANTIBODY MARKET: COMPANY FOOTPRINT 317

TABLE 400         CUSTOM ANTIBODY MARKET: REGION FOOTPRINT     318

TABLE 401         CUSTOM ANTIBODY MARKET: SERVICE FOOTPRINT    319

TABLE 402         CUSTOM ANTIBODY MARKET: TYPE FOOTPRINT          320

TABLE 403         CUSTOM ANTIBODY MARKET: APPLICATION FOOTPRINT              321

TABLE 404         CUSTOM ANTIBODY MARKET: INDICATION FOOTPRINT              322

13.7       COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023          323

13.7.1    PROGRESSIVE COMPANIES       323

13.7.2    RESPONSIVE COMPANIES          323

13.7.3    DYNAMIC COMPANIES 323

13.7.4    STARTING BLOCKS       323

FIGURE 38         CUSTOM ANTIBODY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023           324

13.7.5    COMPETITIVE BENCHMARKING            325

TABLE 405         CUSTOM ANTIBODY MARKET: DETAILED LIST OF KEY STARTUPS/SMES           325

TABLE 406         CUSTOM ANTIBODY MARKET: COMPANY FOOTPRINT (STARTUPS/SMES)        326

13.8       VALUATION AND FINANCIAL METRICS OF CUSTOM ANTIBODY SERVICE VENDORS        326

FIGURE 39         EV/EBITDA OF KEY VENDORS   326

FIGURE 40         YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF  KEY VENDORS           327

13.9       COMPETITIVE SCENARIO          327

13.9.1    DEALS  327

TABLE 407         CUSTOM ANTIBODY MARKET: DEALS, JANUARY 2021–APRIL 2024      327

13.9.2    EXPANSIONS    328

TABLE 408         CUSTOM ANTIBODY MARKET: EXPANSIONS, JANUARY 2021–APRIL 2024        328

14          COMPANY PROFILES    329

14.1       KEY PLAYERS   329

(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*

14.1.1    THERMO FISHER SCIENTIFIC INC.          329

TABLE 409         THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW              329

FIGURE 41         THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)   330

TABLE 410         THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED 330

TABLE 411         THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–APRIL 2024        332

14.1.2    GENSCRIPT       333

TABLE 412         GENSCRIPT: COMPANY OVERVIEW       333

FIGURE 42         GENSCRIPT: COMPANY SNAPSHOT (2023)         334

TABLE 413         GENSCRIPT: SERVICES OFFERED           334

TABLE 414         GENSCRIPT: DEALS, JANUARY 2021–APRIL 2024 335

TABLE 415         GENSCRIPT: EXPANSIONS, JANUARY 2021–APRIL 2024   336

14.1.3    BIO-RAD LABORATORIES, INC. 337

TABLE 416         BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW  337

FIGURE 43         BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)              338

TABLE 417         BIO-RAD LABORATORIES, INC.: SERVICES OFFERED      338

TABLE 418         BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES,

JANUARY 2021–APRIL 2024         339

14.1.4    MERCK KGAA   340

TABLE 419         MERCK KGAA: COMPANY OVERVIEW    340

FIGURE 44         MERCK KGAA: COMPANY SNAPSHOT (2023)      341

TABLE 420         MERCK KGAA: SERVICES OFFERED        341

TABLE 421         MERCK KGAA: DEALS, JANUARY 2021–APRIL 2024           342

TABLE 422         MERCK KGAA: EXPANSIONS, JANUARY 2021–APRIL 2024 342

14.1.5    AGILENT TECHNOLOGIES, INC.             343

TABLE 423         AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 343

FIGURE 45         AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)              344

TABLE 424         AGILENT TECHNOLOGIES, INC.: SERVICES OFFERED    344

14.1.6    REVVITY, INC.   345

TABLE 425         REVVITY, INC.: COMPANY OVERVIEW   345

FIGURE 46         REVVITY, INC.: COMPANY SNAPSHOT (2023)     346

TABLE 426         REVVITY, INC.: SERVICES OFFERED       347

TABLE 427         REVVITY, INC.: DEALS, JANUARY 2021–APRIL 2024           347

14.1.7    BIO-TECHNE    348

TABLE 428         BIO-TECHNE: COMPANY OVERVIEW     348

FIGURE 47         BIO-TECHNE: COMPANY SNAPSHOT (2023)       349

TABLE 429         BIO-TECHNE: SERVICES OFFERED         349

TABLE 430         BIO-TECHNE: DEALS, JANUARY 2021–APRIL 2024            350

14.1.8    ROCKLAND IMMUNOCHEMICALS, INC. 351

TABLE 431         ROCKLAND IMMUNOCHEMICALS, INC.: COMPANY OVERVIEW              351

TABLE 432         ROCKLAND IMMUNOCHEMICALS, INC.: SERVICES OFFERED              351

TABLE 433         ROCKLAND IMMUNOCHEMICALS, INC.: DEALS, JANUARY 2021–APRIL 2024        352

14.1.9    LABORATORY CORPORATION OF AMERICA HOLDINGS             353

TABLE 434         LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW  353

FIGURE 48         LABORATORY CORPORATION OF AMERICA HOLDINGS:

COMPANY SNAPSHOT (2023)    354

TABLE 435         LABORATORY CORPORATION OF AMERICA HOLDINGS: SERVICES OFFERED      355

14.1.10  INOTIV 356

TABLE 436         INOTIV: COMPANY OVERVIEW 356

FIGURE 49         INOTIV.: COMPANY SNAPSHOT (2023)  357

TABLE 437         INOTIV: SERVICES OFFERED     357

TABLE 438         INOTIV: DEALS, JANUARY 2021–APRIL 2024        358

TABLE 439         INOTIV: EXPANSIONS, JANUARY 2021–APRIL 2024           358

14.1.11  DANAHER CORPORATION         359

TABLE 440         DANAHER CORPORATION: COMPANY OVERVIEW         359

FIGURE 50         DANAHER CORPORATION: COMPANY SNAPSHOT (2023)              360

TABLE 441         DANAHER CORPORATION: SERVICES OFFERED 361

TABLE 442         DANAHER CORPORATION: DEALS, JANUARY 2021–APRIL 2024              362

TABLE 443         DANAHER CORPORATION: EXPANSIONS, JANUARY 2021–APRIL 2024      362

14.1.12  SINO BIOLOGICAL, INC.             363

TABLE 444         SINO BIOLOGICAL, INC.: COMPANY OVERVIEW 363

FIGURE 51         SINO BIOLOGICAL, INC.: COMPANY SNAPSHOT (2023)  363

TABLE 445         SINO BIOLOGICAL, INC.: SERVICES OFFERED    364

TABLE 446         SINO BIOLOGICAL, INC.: DEALS, JANUARY 2021–APRIL 2024              365

TABLE 447         SINO BIOLOGICAL, INC.: EXPANSIONS, JANUARY 2021–APRIL 2024      365

14.1.13  KANEKA CORPORATION            366

TABLE 448         KANEKA CORPORATION: COMPANY OVERVIEW             366

FIGURE 52         KANEKA CORPORATION: COMPANY SNAPSHOT (2022) 367

TABLE 449         KANEKA CORPORATION: SERVICES OFFERED   367

14.1.14  ORIGENE TECHNOLOGIES, INC.             368

TABLE 450         ORIGENE TECHNOLOGIES, INC.: COMPANY OVERVIEW 368

TABLE 451         ORIGENE TECHNOLOGIES, INC.: SERVICES OFFERED    368

14.1.15  ABSOLUTE BIOTECH    369

TABLE 452         ABSOLUTE BIOTECH: COMPANY OVERVIEW     369

TABLE 453         ABSOLUTE BIOTECH: SERVICES OFFERED         369

TABLE 454         ABSOLUTE BIOTECH: DEALS, JANUARY 2021–APRIL 2024              370

TABLE 455         ABSOLUTE BIOTECH: EXPANSIONS, JANUARY 2021–APRIL 2024              370

14.1.16  BIOINTRON BIOLOGICS             371

TABLE 456         BIONTRON BIOLOGICS: COMPANY OVERVIEW 371

TABLE 457         BIOINTRON BIOLOGICS: SERVICES OFFERED    371

TABLE 458         BIOINTRON BIOLOGICS: DEALS, JANUARY 2021–APRIL 2024              372

14.2       OTHER PLAYERS           373

14.2.1    CELL SIGNALING TECHNOLOGY, INC.  373

TABLE 459         CELL SIGNALING TECHNOLOGY, INC.: COMPANY OVERVIEW              373

14.2.2    CURIA GLOBAL, INC.     374

TABLE 460         CURIA GLOBAL, INC.: COMPANY OVERVIEW     374

14.2.3    MABTECH         375

TABLE 461         MABTECH: COMPANY OVERVIEW          375

14.2.4    ACROBIOSYSTEMS        376

TABLE 462         ACROBIOSYSTEMS: COMPANY OVERVIEW         376

14.2.5    ELABSCIENCE BIONOVATION INC.        377

TABLE 463         ELABSCIENCE BIONOVATION INC.: COMPANY OVERVIEW              377

14.2.6    CREATIVE DIAGNOSTICS           378

TABLE 464         CREATIVE DIAGNOSTICS: COMPANY OVERVIEW           378

14.2.7    CUSABIO TECHNOLOGY LLC    379

TABLE 465         CUSABIO TECHNOLOGY LLC: COMPANY OVERVIEW     379

14.2.8    BIOGENES GMBH          380

TABLE 466         BIOGENES GMBH: COMPANY OVERVIEW           380

14.2.9    RAYBIOTECH, INC.        381

TABLE 467         RAYBIOTECH, INC.: COMPANY OVERVIEW         381

14.2.10  PROTEINTECH GROUP, INC.     382

TABLE 468         PROTEINTECH GROUP, INC.: COMPANY OVERVIEW      382

14.2.11  IMGENEX INDIA PVT. LTD.        383

TABLE 469         IMGENEX INDIA PVT. LTD.: COMPANY OVERVIEW         383

14.2.12  SYNBIO TECHNOLOGIES           384

TABLE 470         SYNBIO TECHNOLOGIES: COMPANY OVERVIEW            384

14.2.13  PROSCI INCORPORATED           385

TABLE 471         PROSCI INCORPORATED: COMPANY OVERVIEW            385

14.2.14  CREATIVE BIOLABS       386

TABLE 472         CREATIVE BIOLABS: COMPANY OVERVIEW       386

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

15          APPENDIX         387

15.1       DISCUSSION GUIDE      387

15.2       KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL             391

15.3       CUSTOMIZATION OPTIONS      393

15.4       RELATED REPORTS       394

15.5       AUTHOR DETAILS         395

バイオ技術の最新記事8件